Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9.

[1]  M. Howarth,et al.  Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. , 2010, Cancer research.

[2]  O. Larsson,et al.  SUMOylation Mediates the Nuclear Translocation and Signaling of the IGF-1 Receptor , 2010, Science Signaling.

[3]  H. Werner,et al.  The insulin-like growth factor-I receptor as an oncogene , 2009, Archives of physiology and biochemistry.

[4]  Shuomin Zhu,et al.  MicroRNA-mediated Regulation of Ubc9 Expression in Cancer Cells , 2009, Clinical Cancer Research.

[5]  M. Toyoda,et al.  EWS/ETS Regulates the Expression of the Dickkopf Family in Ewing Family Tumor Cells , 2009, PloS one.

[6]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[7]  D. Clemmons,et al.  Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer , 2007, Nature Reviews Drug Discovery.

[8]  S. Reed,et al.  Cyclin E overexpression impairs progression through mitosis by inhibiting APCCdh1 , 2007, The Journal of cell biology.

[9]  D. Jukic,et al.  SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas , 2007, Oncogene.

[10]  O. Larsson,et al.  Role of Ubiquitination in IGF-1 Receptor Signaling and Degradation , 2007, PloS one.

[11]  L. Sistonen,et al.  PDSM, a motif for phosphorylation-dependent SUMO modification. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Ulrich.  Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. , 2005, Trends in cell biology.

[13]  Y. Mo,et al.  A role for Ubc9 in tumorigenesis , 2005, Oncogene.

[14]  Mark W Tengowski,et al.  Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871 , 2005, Clinical Cancer Research.

[15]  M. Hung,et al.  Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.

[16]  A. Zetterberg,et al.  Mutation of hCDC4 Leads to Cell Cycle Deregulation of Cyclin E in Cancer , 2004, Cancer Research.

[17]  Yoshiharu Matsuura,et al.  Sumoylation is involved in β‐catenin‐dependent activation of Tcf‐4 , 2003 .

[18]  R. Honda,et al.  Sumoylation of Mdm2 by Protein Inhibitor of Activated STAT (PIAS) and RanBP2 Enzymes* , 2002, The Journal of Biological Chemistry.

[19]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[20]  P. Maher,et al.  Importin β–Mediated Nuclear Import of Fibroblast Growth Factor Receptor , 2001, The Journal of Cell Biology.

[21]  M. O’Connor-McCourt,et al.  Predominant intracellular localization of the type I transforming growth factor-beta receptor and increased nuclear accumulation after growth arrest. , 2000, Experimental cell research.

[22]  R. Baserga.  The IGF-I receptor in cancer research. , 1999, Experimental cell research.

[23]  R. Hay,et al.  Identification of the Enzyme Required for Activation of the Small Ubiquitin-like Protein SUMO-1* , 1999, The Journal of Biological Chemistry.

[24]  N. Webster,et al.  Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. , 1998, Cancer research.

[25]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[26]  B. Gliozzo,et al.  Insulin‐like Growth Factor‐I (IGF‐I) Receptors in Breast Cancer , 1996, Annals of the New York Academy of Sciences.

[27]  T. Kaji,et al.  Vascular smooth muscle cells in culture are highly sensitive to cadmium cytotoxicity without species-related differences: comparison with Chang liver cells. , 1995, Biological and Pharmaceutical Bulletin.

[28]  M. Boccadoro,et al.  The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. , 1989, Blood.

[29]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[30]  G. Moore,et al.  Production of Free Light Chains of Immunoglobulin by a Hematopoietic Cell Line Derived from a Patient with Multiple Myeloma.∗ , 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[31]  Yusuke Nakajima,et al.  Co‐regulation of B‐Myb expression by E2F1 and EGF receptor , 2006, Molecular carcinogenesis.

[32]  Yoshiharu Matsuura,et al.  Sumoylation is involved in beta-catenin-dependent activation of Tcf-4. , 2003, The EMBO journal.

[33]  P. Maher,et al.  Importin beta-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. , 2001, The Journal of cell biology.

[34]  H. Werner,et al.  The role of the insulin-like growth factor system in human cancer. , 1996, Advances in cancer research.